Guerbet

58 articles with Guerbet

• Guerbet: 2022 annual results

  3/22/2023

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, has published its consolidated financial statements for the 2022 fiscal year.

• Guerbet Announces Commercial Launch and First Patient Dosing of Elucirem™ (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging (MRI)

  2/13/2023

  Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the commercial launch and dosing of the first patient with Elucirem™ (gadopiclenol) injection following FDA approval in 2022.

• Guerbet: 2022 revenue

  2/9/2023

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, has reported its annual revenue.

• Guerbet: 2023 Strategic Priorities

  1/16/2023

  Guerbet, a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.

• Guerbet: Revenue at September 30, 2022

  10/20/2022

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, reported its revenue for the first 9 months of 2022.

• Guerbet: 2022 half-year results

  9/21/2022

  Villepinte, Wednesday, September 21, 2022: Guerbet, a global specialist in contrast agents and solutions for medical imaging, is announcing its consolidated results for the first half of 2022.

• Guerbet: Revenue at June 30, 2022

  7/21/2022

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, reports its revenue for the first half of 2022.

• Guerbet: Q1 2022 revenue

  4/21/2022

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, reports its revenue for first-quarter 2022.

• Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA

  3/29/2022

  Guerbet has recently submitted a New Drug Application to the U.S. Food and Drug Administration and a Centralized Application for Marketing Authorization to the European Medicine Agency for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent.

• Guerbet: 2021 annual results

  3/23/2022

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, is announcing its consolidated annual results for 2021.

• Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

  12/14/2021

  Guerbet and Bracco Imaging announced they have signed a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging contrast agent.

• Guerbet: Revenue at September 30, 2021

  10/21/2021

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, reported its sales for the first nine months of the year.

• 

  BioSpace Movers & Shakers, June 4

  6/4/2021

  Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
• 

  Clinical Catch-Up: March 22-26

  3/29/2021

  There was a fair amount of clinical trial news last week. Here’s a look.

• Guerbet to Showcase its UNIK Solution at RSNA 2020

  11/12/2020

  Guerbet a global leader in medical imaging, announced that it will highlight UNIK, a tailored solution for diagnostic imaging, at the 2020 annual meeting of the Radiological Society of North America.

• 

  BioSpace Global Roundup, June 18

  6/18/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
• 

  BioSpace Global Roundup, May 21

  5/21/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
• 

  BioSpace Global Roundup, March 26

  3/26/2020

  Pharma and life sciences companies from across the globe provide updates on their pipelines and business practices.

• Guerbet To Showcase Next Generation Digital Solutions at HIMSS20

  2/26/2020

  Contrast&Care®, Dose&Care® heighten performance, increase productivity, and improve patient care, while IBM Watson Imaging Patient Synopsis provides relevant patient information to Radiologists to help inform clinical care decisions.

• Guerbet Announces Appointment of Thomas McLaughlin as Vice President for North America

  1/8/2020

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced that Thomas McLaughlin has been appointed Vice President, North America.